Reading...
Play button
Play button
Use LEFT and RIGHT arrow keys to navigate between flashcards;
Use UP and DOWN arrow keys to flip the card;
H to show hint;
A reads text to speech;
19 Cards in this Set
- Front
- Back
|
CHOLORPROMAZINE
|
FIRST ANTISCHIZOPHRENIC DRUG
|
|
|
RESERPINE
|
THE FIRST MONOAMINE ANTAGONIST TO BE USED IN THE TREATMENT OF SCHIZOPHRENIA
ACTIVE INGREDIENT OF THE SNAKE ROOT PLANT |
|
|
HALOPERIDOL
|
A BUTYROPHENONE THAT WAS USED AS AN ANTISCHIZOPHRENIC DRUG
|
|
|
PHENOTHIAZINES
|
A CLASS OF ANTISCHIZOPHRENIC DRUGS THAT BIND EFFECTIVELY TO BOTH D1 AND D2 RECEPTORS
|
|
|
BUTYROPHENONES
|
A CLASS OF SCHIZOPHRENIC DRUGS THAT BIND PRIMARILY TO D2 RECEPTORS
|
|
|
NEUROLEPTICS
|
DRUGS THAT ALLEVIATE SCHIZOPHRENIC SYMPTOMS
|
|
|
CLOZAPINE
|
AN ATYPICAL NEUROLEPTIC THAT IS USED TO TREAT SCHIZOPHRENIA, DOES NOT PRODUCE PARKINSONS SIDE EFFECTS, AND DOES NOT HAVE A HIGH AFFINITY FOR D2 RECEPTORS
|
|
|
IPRONIAZID
|
THE FIRST ANTIDEPRESSANT DRUG
MONOAMINE OXIDASE INHIBITOR |
|
|
MAO INHIBITORS
|
ANTIDEPRESSANT DRUGS THAT INCREASE THE LEVEL OF MONAMINE NEUROTRANSMITTERS BY INHIBITING THE ACTION OF MONOAMINE OXIDASE
|
|
|
CHEESE EFFECT
|
THE SRUGES IN BLOOD PRESSURE THAT OCCUR WHEN INDIVIDUALS TAKING MAO INHIBITORS CONSUME TYRAMINE RICH FOODS, SUCH AS CHEESE
|
|
|
TRICYCLIC ANTIDEPRESSANTS
|
DRUGS WITH AN ANTIDEPRESSANT ACTION AND A THREE RING MOLECULAR STRUCTURE
SELECTIVELY SUPPRESS REM SLEEP |
|
|
IMIPRAMINE
|
THE FIRST TRICYCLIC ANTIDEPRESSANT DRUG
|
|
|
PROZAC
|
THE TRADE NAME OF FLUOXETINE,
FIRST SSRI DEVELOPED FOR DEPRESSION |
|
|
UP-REGULATION
|
AN INCREASE INT HE NUMBER OF RECEPTORS FOR A NT IN RESPONSE TO DECREASED RELEASE OF THAT NT
|
|
|
BENZODIAZEPINES
|
A CLASS OF GABA AGONISTS WITH ANXIOLYTIC, SEDATIVE, AND ANTICONVULSANT PROPERTIES
CHLORDIAZEPOXIDE (LIBRIUM) DIAZEPAM (VALIUM) |
|
|
RISK-ASSESSMENT TEST
|
AN ANIMAL MODEL OF ANXIETY; ANXIOUS RATS CAREFULLY OBSERVE AN OPEN ENVIRONMENT BEFORE VENTURING INTO IT
|
|
|
TRANSLATIONAL RESEARCH
|
RESEARCH DESIGNED TO TRANSLATE BASIC SCIENTIFIC DISCOVERIES INTO EFFECTIVE APPLICATIONS
|
|
|
ORPHAN DRUGS
|
DRUGS FOR WHICH THE MARKET IS TOO SMALL FOR THE NECESSARY DEVELOPMENTAL RESEARCH TO BE PROFITABLE
|
|
|
TRANSLATIONAL BOTTLENECK
|
A BARRIER KEEPING PROMISING IDEAS AND TREAMTNETS FROM BECOMING THE FOCUS OF TRANSLATIONAL RESEARCH
CREASED BY MASSIVE COST OF SUCH RESEARCH |
